Article Text

Download PDFPDF

EP197/#453  Economic burden of management of platinum-resistant or -refractory ovarian cancer: an update of a systematic literature review
  1. Nikhila Indukuri1,
  2. Zhiyuan Chen2 and
  3. Melissa Payer3
  1. 1Novocure Ltd, Global Value, New York, USA
  2. 2Cytel, Inc., Heor, Waltham, USA
  3. 3Novocure Ltd, Global Market Access, Portsmouth, USA


Introduction Platinum-resistant or -refractory ovarian cancer (PROC) is associated with a considerable economic burden, including high costs of treatment. Here we present the results from an update of a systematic literature review (SLR) conducted to characterize the costs associated with the management of PROC.

Methods The initial SLR included studies published January 2010-July 6, 2021, and the current update included studies from July 2021 to March 2, 2023. MEDLINE®, Embase®, EconLit, Cochrane, and relevant conference proceedings were searched for economic evaluations and studies reporting costs associated with the treatment of advanced ovarian cancer recurring within six months of the last platinum-based chemotherapy. The SLR was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement.

Results A total of 19 records from 18 studies were included, two of which were US cost-effectiveness analyses (CEAs) from the updated SLR. A 2022 US CEA reported that olaparib was cost-effective vs niraparib for BRCA1 and BRCA2-mutation-positive PROC at a willingness-to-pay threshold of $100,000. In another CEA from 2022, total parenteral nutrition was not cost-effective for the management of inoperable malignant bowel obstruction in PROC. Overall, the cost-per-cycle for PROC treatment ranged from $53 to $4,360 for chemotherapy, $6,989 to $9,806 for bevacizumab, and $7,780 to $9,022 for poly-(adenosine diphosphate-ribose) polymerase inhibitors (figure 1). Reported incremental cost-effectiveness ratios were high and most interventions were not considered cost effective (table 1).

Conclusion/Implications High healthcare and treatment costs associated with the management of PROC emphasize the need for cost-effective treatment options in PROC.

Abstract EP197/#453 Table 1

Cost-effectiveness of PROC therapies reported in the studies included in the SLR

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.